60+ Deaths Linked to Ozempic, Wegovy, Mounjaro in Australia: Your Pre-Start Safety Checklist

Australia's drug regulator has now linked more than 60 reported deaths to GLP-1 medications like Ozempic, Wegovy, and Mounjaro. That headline alone is enough to make anyone considering these drugs pause.

But here's what almost nobody tells you: most of the serious harm reports share a handful of avoidable patterns, skipped bloodwork, ignored warning signs, dose jumps that were too fast, and zero screening for the conditions that make these drugs genuinely dangerous for certain people. This isn't a reason to panic. It's a reason to build a real safety protocol before you ever pick up a pen or vial.

Important: I'm not a doctor. Everything below is based on published research and regulatory reporting, not personal medical advice. Talk to your physician before starting or changing any GLP-1 regimen.

The Bottom Line

• Over 60 deaths have been reported to Australia's Therapeutic Goods Administration (TGA) in connection with GLP-1 drugs, but "reported" does not mean "proven caused by." Adverse event reports capture anything that happened after a drug was used, not confirmed cause and effect.
• Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved for type 2 diabetes and/or weight management, but approval doesn't mean risk-free, especially without proper screening.
• Most serious complications tied to these drugs involve a small, identifiable list of risk factors: pancreatitis history, gallbladder disease, thyroid cancer family history, severe GI conditions, and rapid dose escalation.
• The single most actionable step you can take today: get baseline bloodwork (pancreatic enzymes, liver panel, kidney function) and a gallbladder/thyroid history review before your first dose, not after side effects start.
• If you're already on a GLP-1, know the five red-flag symptoms that mean "call a doctor now," covered below.

What Actually Happened in Australia

Australia's TGA, similar to the FDA in the U.S., collects voluntary adverse event reports from doctors, pharmacists, and patients. As GLP-1 prescriptions have exploded (Ozempic and Mounjaro searches are still among the most Googled drug names worldwide), the number of reports tied to these drugs has climbed right along with usage.

More than 60 deaths have now been reported to the TGA in association with semaglutide and tirzepatide use. That number sounds alarming on its own, but it needs context most headlines skip.

Adverse event databases record temporal association, not causation. If someone taking Ozempic dies of a heart attack six months later, that can still get logged as a reported death "associated with" the drug, even if the drug had nothing to do with it. Millions of people are now on these medications, many with pre-existing heart disease, diabetes complications, or other risk factors that predate the prescription.

That said, dismissing the number entirely would be a mistake too. A systematic review on GLP-1 receptor agonists and suicidality found the signal worth continued monitoring, and pancreatitis, gallbladder disease, and severe GI events are well-documented, real risks, not rare theoretical ones. The honest takeaway: these are powerful drugs that work well for most people, but they are not risk-free, and the people who get hurt often share preventable risk factors.

For more on what side effects actually look like in practice, see GLP-1 side effects: what to expect.

The Practical Protocol: What to Do Before Your First Dose

This is the part that matters most. If you're going to start a GLP-1, do these five things first, in this order.

Step 1: Get baseline labs, not just a prescription

Before starting, ask your doctor for:

• Lipase and amylase (pancreatic enzyme markers, flags pancreatitis risk early)
• Full liver panel (ALT, AST, bilirubin)
• Kidney function (creatinine, eGFR)
• Thyroid history review, especially family history of medullary thyroid carcinoma or MEN2 syndrome, this is an actual contraindication for semaglutide and tirzepatide

Most people never get this baseline. It takes one blood draw and gives you and your doctor something to compare against if symptoms show up later.

Step 2: Screen for the conditions that make these drugs risky

You should have an honest conversation with your prescriber about:

• History of pancreatitis (any cause, including alcohol-related)
• Gallstones or gallbladder disease
• Severe gastroparesis or other motility disorders
• Personal or family history of thyroid cancer
• Eating disorder history (rapid, severe appetite suppression can be dangerous here)

None of these automatically rule you out, but they change how closely you should be monitored.

Step 3: Start low and go slow, even if you want faster results

The single biggest mistake people make is rushing their own titration schedule. Manufacturer titration schedules exist because the body needs time to adjust GI motility and hormone signaling. Jumping doses early dramatically increases nausea, vomiting, and dehydration risk, and dehydration is a known contributor to kidney injury reports.

Stick to the approved schedule (typically 4-week increments) unless your doctor has a specific reason to move faster.

Step 4: Hydrate and eat enough, this isn't optional

Severe vomiting and diarrhea from GLP-1 use, combined with reduced fluid intake from appetite suppression, is one of the most common paths to hospitalization. Aim for consistent fluid intake and don't let appetite loss turn into near-zero food intake, that's a separate problem from normal reduced hunger.

Step 5: Schedule a 4-6 week check-in, not just a refill call

Most adverse events get caught late because the only contact with a provider is a pharmacy refill. Book an actual follow-up appointment in the first month to review side effects, weight trend, and labs if anything felt off.

For a deeper look at long-term risk profiles by drug, see semaglutide side effects long-term and tirzepatide side effects long-term.

Common Mistakes That Turn a Low-Risk Drug Into a High-Risk One

• Buying from unverified online sources. Compounded or gray-market versions carry contamination and dosing accuracy risks that brand-name pharmacy products don't. If you're using a compounded version, verify the pharmacy is legitimate, see our breakdown on compounded semaglutide safety and quality.
• Self-adjusting doses to "speed up" results. This is the single most preventable cause of severe GI events.
• Ignoring persistent abdominal pain. People often chalk this up to normal nausea and wait too long to call a doctor.
• Skipping the follow-up because "everything feels fine." Silent kidney or liver changes don't always come with symptoms early on.
• Not disclosing other medications. GLP-1 drugs slow stomach emptying, which changes how other oral medications get absorbed, this matters especially for insulin, sulfonylureas, and blood thinners.

Red-Flag Symptoms: When to Call a Doctor Immediately

If you're already taking a GLP-1 drug, stop and call your doctor (or seek urgent care) if you notice:

1. Severe, persistent upper abdominal pain that radiates to your back, a classic pancreatitis warning sign
2. Yellowing skin or eyes, possible gallbladder or liver involvement
3. Signs of severe dehydration, dizziness, dark urine, confusion, rapid heartbeat
4. A new lump in your neck or hoarseness that doesn't resolve, thyroid-related concern
5. Sudden mood changes, hopelessness, or thoughts of self-harm, take this seriously and reach out immediately; this is part of why ongoing research is tracking mental health signals with these drugs

None of these symptoms mean panic is warranted; but none of them should be ignored either.

Who Should Probably Wait or Choose a Different Path

Based on current research and the risk factors most often flagged in adverse event data, a conversation with your doctor about alternatives makes sense if you have:

• Active or recent pancreatitis
• A personal or family history of medullary thyroid cancer or MEN2
• Severe, unmanaged gastroparesis
• A history of restrictive eating disorders
• Plans for major surgery in the near future, where GLP-1 use affects anesthesia safety protocols

This isn't a permanent "no" for everyone on that list, it's a "this needs a specialist conversation first."

FAQ

Does this mean Ozempic or Mounjaro caused 60+ deaths in Australia? No. The TGA reports are "associated with" reports, meaning the drug was in someone's system when the event happened, not confirmed proof the drug caused it. Regulators investigate these signals over time, but reported association and confirmed causation are different things.

Are Ozempic, Wegovy, and Mounjaro FDA-approved? Yes, for their specific approved uses, semaglutide for type 2 diabetes (Ozempic) and chronic weight management (Wegovy), and tirzepatide for type 2 diabetes (Mounjaro) and weight management (Zepbound). Approval applies to those indications, following prescribed dosing.

What's the most common serious side effect people should watch for? Pancreatitis and severe gallbladder issues show up most consistently in safety literature. Persistent abdominal pain is the symptom to take seriously.

Should I stop my GLP-1 medication because of this news? Don't stop abruptly without talking to your doctor first, sudden discontinuation has its own risks, including rebound weight regain and blood sugar swings. Bring this data to your next appointment instead.

Is compounded semaglutide riskier than the brand-name version? It can be, mainly due to inconsistent sourcing and dosing accuracy at unverified pharmacies. Quality varies a lot by source, read more here.

Next Step

If you're starting a GLP-1 soon, don't wait for symptoms to build your safety plan, book the baseline labs and the 4-6 week follow-up before day one. If you're already on one, screenshot the red-flag list above and keep it somewhere you'll actually see it.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research, not medical recommendations.

Sources

1. Weight-loss-independent actions of GLP-1 medicines, Cell Metabolism, 2026
2. Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review, Obesity Reviews, 2026
3. Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review, Diabetes, Obesity & Metabolism, 2026
4. Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies, Clinics in Dermatology, 2026
5. Clinical Potential of GIP in Type 2 Diabetes and Obesity, Diabetes Care, 2026